

Advancing Manufacture of Cell and Gene Therapies VIII

Coronado, California, USA
4-8 February 2024

ISBN: 978-1-7138-9861-0

Printed from e-media with permission by:

Curran Associates, Inc.
57 Morehouse Lane
Red Hook, NY 12571



Some format issues inherent in the e-media version may also appear in this print version.

Copyright© (2024) by Engineering Conferences International
All rights reserved.

Printed with permission by Curran Associates, Inc. (2025)

For permission requests, please contact Engineering Conferences International
at the address below.

Engineering Conferences International
32 Broadway, Suite 314
New York, NY 10004
USA

Phone: (212) 514-6760
Fax: (212) 514-6030

info@engconfintl.org

Additional copies of this publication are available from:

Curran Associates, Inc.
57 Morehouse Lane
Red Hook, NY 12571 USA
Phone: 845-758-0400
Fax: 845-758-2633
Email: curran@proceedings.com
Web: www.proceedings.com

Saturday, February 3, 2024

17:30 – 19:30 Welcome Reception (Cays Lounge located beyond the grand staircase)
(Please pick up your badge from an ECI staff member in Cays Lounge)

Sunday, February 4, 2024

08:30 – 16:15 **Pre-Conference Workshop** (Avalon Room)
Building a flexible manufacturing strategy to navigate turbulent global markets

Chairs: Taby Ahsan, City of Hope, USA
Anne-Lise Brondel, Kyowa Kirin, USA
Mercedes Segura, Elevate Bio, USA
Veena Warikoo, AstraZeneca, USA

14:30 Conference check-in (Atrium)

16:45 – 17:00 Conference welcome
Chairs: Fernanda Masri, Cytomos, United Kingdom
Carolyn Yeago, CY Solutions LLC, USA
Gargi Maheshwari, BMS, USA
John Moscariello, BMS, USA

ECI Technical Liaison: Barry Buckland, NIIMBL, USA

Student Liaison: Bryan Wang, TreeFrog Therapeutics, USA

17:00 – 18:00 **Fireside Chat**
A recap of the last 2 years and outlook into the future of cell and gene therapies

Moderator: Fernanda Masri, Cytomos, United Kingdom
Panelists: Gregg Nyberg, Landmark Bio, USA
Bryan Poltilove, PBS Biotech, USA
Chris Ramsborg, Flagship Pioneering, USA

18:00 – 18:30 Stretch Break

18:30 – 20:00 Dinner

Monday, February 5, 2024

- 07:00 – 08:30 Breakfast (Breakfast with VIPs for graduate students)
- Session 1: Viral Vector and Gene Editing Platforms – Progress and Challenges in Process Development, Manufacturing, Product Characterization and Technology Landscape**
Chairs: Alina Verano, Vvector Bio, Canada
Daniel M Marasco, Eli Lilly and Company, USA
- 08:30 – 09:05 **Keynote**
Time is muscle: Platform advancement for swift time-to-market in AAV manufacturing...N/A
Jiuyi Lu, Sarepta Therapeutics, USA
- 09:05 – 09:25 **Continuous processing of viral gene therapy vectors...1**
Caryn Heldt, Michigan Technological University, USA
- 09:25 – 09:45 **Leveraging a RNA-based lipid nanoparticle (LNP) gene writer system to generate Chimeric Antigen Receptor T cells (CAR-T) for in vitro and in vivo tumor activity...2**
Jason Rodriguez, Tessera Therapeutics, USA
- 09:45 – 11:05 Coffee Break / Opportunity to visit sponsor tables
- 11:05 – 11:25 **Enhancing rAAV biomanufacturing: Process intensification strategies for streamlined upstream and downstream processing...3**
António Roldão, iBET, Portugal
- 11:25 – 12:00 **Keynote**
Novel single plasmid technology for AAV production in HEK-293 suspension cells...N/A
Alina Venereo Sanchez, VVector Bio, Canada
- 12:00 – 12:20 **Towards a scalable AAV vector production at high volumetric efficiency...4**
Prasanna Srinivasan, Massachusetts Institute of Technology, USA
- 12:20 – 12:35 Panel Session
- 12:35 – 14:05 Lunch
- Session 2: Advances in Cell Therapy Manufacturing Technology to Enable Autologous and Allogeneic Applications**
Sponsored by PBS Biotech
Chairs: Bruno Marques, Century Therapeutics, USA
Samin Akbari, Sartorius, USA
- 14:05 – 14:40 **Keynote**
Fit for purpose, DMSO-free preservation of cellular therapies...5
Alison Hubel, University of Minnesota, USA
- 14:40 – 15:00 **High-density microbioreactor process designed for automated point-of-care manufacturing of CAR T cells...6**
Wei-Xiang Sin, Singapore-MIT Alliance for Research and Technology Centre (SMART), Singapore

Monday, February 5, 2024 (continued)

- 15:00 – 15:20 **Scalable allogeneic CAR-T manufacturing: Perfusion optimization, multi-liter scale-up and automated harvesting in single-use stirred-tank bioreactors...7**
Pierre Springuel, University College London, United Kingdom
- 15:20 – 15:40 **Producing IpSC derived functional Cd8+ T-cells in scalable stirred tank bioreactors...8**
Liz Csaszar, Notch Therapeutics, Canada
- 15:40 – 16:00 **Assessing robust bioprocess design through modulation of process input variables in the expansion of human induced pluripotent stem cell aggregates in Vertical-Wheel(R) bioreactors...9**
Tiffany Dang, University of Calgary, Canada
- 16:00 – 16:45 Coffee Break / Opportunity to visit sponsor tables
Sponsored by Cell and Gene Therapy Catapult
- 16:45 – 17:20 **Keynote**
Powerful characterization of cell therapies via whole and single-cell next-generation sequencing...10
Tom Brieva, Resilience, USA
- 17:20 – 17:40 **Optimizing the generation of hematopoietic progenitor cells from pluripotent stem cells in dynamic suspension culture...11**
Thristan Paulo Taberna, University of British Columbia, Canada,
- 17:40 – 18:00 **Combined Wnt activation and oxygen modulation enhance the manufacture and scale-up of pluripotent stem cell-derived cardiomyocytes in bioreactors...12**
Pedro Vicente, iBET, Portugal
- 18:00 – 18:20 **Towards a scalable, closed and automated platform for the production of cost-efficient allogeneic cell therapies: showcase of an exemplar iNK process...13**
Márcia F. Mata, Cell and Gene Therapy Catapult, United Kingdom
- 18:20 – 18:30 Stretch Break
- 18:30 – 19:30 **Poster Session** with refreshments & open bar (beer and wine)
Sponsored by Takeda
Chairs: Gargi Maheshwari, BMS, USA
 John Moscariello, BMS, USA
- 19:30 Dinner on your own

Tuesday, February 6, 2024

- 07:00 – 08:30 Breakfast
- Session 2: Advances in Cell Therapy Manufacturing Technology to Enable Autologous and Allogeneic Applications (continued)**
Chairs: Bruno Marques, Century Therapeutics, USA
Samin Akbari, Sartorius, USA
- 08:30 – 09:05 **Keynote**
Bioprocessing of stem-cell derived allogeneic cell therapy products: enabling large-scale manufacturing...14
Mats Åkesson, Novo Nordisk, Denmark
- 09:05 – 09:25 **Stem cell-derived pancreatic Islet encapsulation technologies for immobilized culture and transplantation...15**
Corinne A. Hoesli, McGill University, Canada
- 09:25 – 09:45 **Cell culture media-based cryo-formulations containing dimethyl sulfoxide minimize cryopreservation-induced cell damage in iPSC-derived effector cells...16**
Victoria Karakis, Century Therapeutics, USA
- 09:45 – 10:05 **Effects of temperature fluctuations on cryopreserved human induced pluripotent stem cells Post-thaw viability and cryo-Raman observation...17**
Jun Okuda, Osaka University, Japan
- 10:05 – 10:20 Panel Session
- 10:20 – 11:05 Coffee Break / Opportunity to visit sponsor tables
Sponsored by Resilience
- Session 3: Digitization, Process Control, and Closed-system Automation in Cell and Gene Therapies**
Chairs: Antinea Chair, Cellares, USA
Stephen Balakirsky, Georgia Tech Research Institute, USA
- 11:05 – 11:40 **Keynote**
Modular sensing, automation, and control for the production of cellular therapies...18
Stephen Balakirsky, Georgia Tech Research Institute, USA
- 11:40 – 12:00 **Digital twin-enabled feedback-controlled bioreactors with integrated process analytics for biomanufacturing of cell therapies...34**
Bryan Wang, TreeFrog Therapeutics, USA
- 12:00 – 12:35 **TBA**
- 12:35 – 12:55 **Scaling AAV viral vector production processes up to manufacturing scale utilizing dynadribe single-use bioreactors...35**
Paula Decaria, Thermo Fisher Scientific, USA
- 12:55 – 14:25 Lunch with **Poster Session**

Wednesday, February 7, 2024

- 07:00 – 08:30 Breakfast
- Session 4: In-Process and Analytical Control Strategies for Cell and Gene Therapies (continued)**
Chairs: Paula Alves, iBET, Portugal
Tomas Kowski, Umoja Therapeutics, USA
- 08:30 – 09:05 **Keynote**
Release and characterization of VivoVec: Surface-engineered lentiviral vector for in vivo generation of CAR-T cells...N/A
Richard Rogers, Umoja Biopharma, USA
- 09:05 – 09:25 **TBA**
- 09:25 – 10:00 **Keynote**
Leveraging cell and gene therapy products' quality through a bioanalytics avenue...40
Patricia Gomes-Alves, iBET, Portugal
- 10:00 – 10:20 **Novel analytics for rapid adventitious agent detection in cell and gene therapy manufacturing...41**
Stacy Springs, Massachusetts Institute of Technology, USA
- 10:20 – 11:05 Coffee Break / Opportunity to visit sponsor tables
- 11:05 – 11:40 **Keynote**
New methods and approaches for the analysis of new therapeutic modalities...N/A
Sunny Zhou, Northeastern University, USA
- 11:40 – 12:00 **Process analytical utility of Raman microscopy for cell therapy manufacturing...42**
James M. Piret, University of British Columbia, Canada
- 12:00 – 12:15 Panel Session
- 12:15 – 13:45 Lunch
- 13:45 – 14:15 **Advancing Manufacture of Cell and Gene Therapies Award Lecture: R&D supporting translation of cell based biotherapeutics...43**
Paula Alves, iBET, Portugal
- 14:15 – 15:00 Coffee Break
- Session 5: Critical Early Decisions in Regulatory Strategies and Standards to Facilitate Product Development**
Chairs: Taby Ahsan, City of Hope, USA
Eytan Abraham, Resilience, USA
- 15:00 – 15:35 **Keynote**
NIST flow cytometry standards consortium enables quantitative and comparable characterization of cell and gene therapies...44
Lili Wang, NIST, USA

Wednesday, February 7, 2024 (continued)

- | | |
|---------------|---|
| 15:35 – 16:10 | Keynote
Reducing regulatory risk with CMC strategy using gene therapy platforms...N/A
Doris Snow, Resilience, USA |
| 16:10 – 16:45 | Keynote
Regulatory updates and trends in cell and gene therapy...45
Kimberly Benton, Dark Horse Consulting, USA |
| 16:45 – 16:50 | Workshop output
Anne-Lise Brondel, Kyowa Kirin, USA and Taby Ahsan, City of Hope, USA |
| 16:50 – 17:30 | Panel Discussion |
| 17:30 – 19:00 | Break |
| 19:00 | Conference Banquet |

Thursday, February 8, 2024

- | | |
|-------|-------------------------|
| 07:00 | Breakfast and Departure |
|-------|-------------------------|

Poster Presentations

1. **Scalable manufacturing of extracellular vesicles from human-induced pluripotent stem cells in stirred-tank bioreactors...62**
Margarida Serra, iBET-Instituto de Biologia Experimental e Tecnológica, Portugal
2. **T cell expansion and phenotype can be tuned in stirred-tank bioreactors through temporal control of T cell activation...63**
Margarida Serra, iBET-Instituto de Biologia Experimental e Tecnológica, Portugal
3. **Method development for the production of clinically relevant doses of human pluripotent stem cell derived cardiomyocytes...64**
Andrew Prowse, The University of Queensland, Australia
4. **Flow-based membrane technology to engineer T-cells...65**
Aida López Ruiz, University of Delaware, USA
5. **Development of a xeno free system for scale-up of human bone marrow derived mesenchymal stromal cells using dissolvable microcarriers in a single-use vertical wheel bioreactor...66**
Antonio Fernandez-Perez, Corning Life Sciences, USA
6. **Gradient plasma polymer coatings as closed culture vessel surface for manufacturing cell-based immunotherapy products...67**
Balaji Ramachandran, McGill University, Canada
7. **Systematic bioprocess engineering used to optimize linear scale-up of size controlled PSC aggregates in vertical-wheel bioreactors...68**
Breanna Borys, PBS Biotech Inc., USA
8. **Recombinant carbohydrate binding module fusion proteins for the animal-component-free bioprocessing of stem cells...69**
Brett Abraham, University of Calgary, Canada
9. **Ambr250 system for optimization of stem cell aggregate expansion conditions...70**
Brian Russell, Astrazeneca, USA
10. **Process optimization in enhancing end-stage iPSC-derived immune-effector cell expansion...71**
Chen-Yuan Kao, Century Therapeutics, USA
11. **Process parameter development for the scaled generation of stem cell-derived pancreatic endocrine cells...72**
Diepiriye Iworima, University of British Columbia, Canada
12. **An optimized bioprocess for the transplantation of autologous bone-marrow derived mesenchymal stromal cells to treat equine joint injury...73**
Emilie Gysel, University of Calgary, Canada
13. **Enabling allogeneic T cell-based therapies: Scalable stirred-tank bioreactor mediated manufacturing...74**
Lisa Prendergast, Lonza, United Kingdom
14. **A platform approach for producing engineered extracellular vesicles...75**
Lisa Prendergast, Lonza, United Kingdom

15. **Designing a feeder-free expansion system for peripheral blood-derived NK cells...76**
Janani Narayan, University of Minnesota, USA
16. **Designing a soluble factor-based expansion system through mechanistic understanding of feeder cell-mediated NK cell activation...77**
Janani Narayan, University of Minnesota, USA
17. **Amino acid analysis indicates metabolic differences in multi-cytokine backpack-manufactured CAR T-cells...78**
Milla Neffling, 908 Devices, Inc., USA
18. **Optimization of cell culture conditions for high transfection efficiency of HEK293 cells and production of viral vectors...79**
Milla Neffling, 908 Devices, Inc., USA
19. **Addressing scale-up challenges for the production of allogeneic, shear sensitive cell therapy products within the Vertical-Wheel bioreactor family...80**
Omokhowa Agbojo, PBS Biotech Inc., USA
20. **Understanding oxygen tension impact for enhanced clinical scale hematopoietic progenitor cell differentiation...81**
Orchid Poponne, Century Therapeutics, USA
21. **Comparison of growth activity of bone marrow-derived mesenchymal stem cells in normoxic and hypoxic culture conditions through continuous passage...82**
Rafianto Dwi Cahyo, Osaka University, Japan
22. **Development of mass culture process for human induced pluripotent stem cells in suspension...83**
Riku Yamamoto, Osaka University, Japan
23. **Investigate the stability of seeding process of mesenchymal stem cell on microcarriers by considering heterogeneity...84**
Riku Yamamoto, Osaka University, Japan
24. **Verification of built-in calibration function of a pH sensor for sample-free bioprocess operations...85**
CD Feng, Broadley-James Corp., USA
25. **Building global opportunities between development and quality (Qualified Persons, QPs) for ATMPs...86**
Tiffany Rau, Biopharma Technical Consulting Ltd (Ireland) and Rau Consulting LLC (USA), Ireland
26. **Automated TruStable™ rAAV production...87**
Christopher Abeles, Shape Therapeutics, USA
27. **Use of conventional flow cytometry to study extracellular vesicles...88**
Gregg Nyberg, Landmark Bio, USA
28. **At-line quantitation for the nicotinic acid to nicotinamide ratio as a biomarker for microbial combination of cell cultures...89**
Kenion Blakeman, 908 Devices, Inc., USA

29. **Improving cell and gene therapy manufacturing processes by automated on-line and in-line bioprocess analytical technologies...90**
Nick Randall, 908 Devices, Inc., USA
30. **WITHDRAWN**
31. **Adsorptive separation of viral gene therapy vectors...91**
Nico Lingg, BOKU, Austria
32. **Screen your AAV production process – From high throughput to scalability...92**
Alyssa Buve, Sartorius Xell GmbH, Germany
33. **Development of a scale down bioreactor model for AAV gene therapy...93**
Arun Bagale, Rocket Pharmaceuticals, Inc., USA
34. **Utilizing enhancers to elevate AAV productivity...94**
Brandi Arterberry, Rocket Pharmaceuticals, Inc., USA
35. **Strategies for enhanced Adeno-Associated Virus (AAV) vector formulations...95**
Braulio Carrillo Sanchez, University College London, United Kingdom
36. **A scalable 3-D printed bioreactor for adherent cell based production of viral vector...96**
Carlos Cantú, Southwest Research Institute, USA
37. **Optimizing triple transfection for enhanced rAAV production: A Response Surface Methodology approach...97**
Jesús Lavado García, Technical University of Denmark, Denmark
38. **WITHDRAWN**
39. **WITHDRAWN**
40. **A recombinase-mediated cassette exchange capable stable cell line for configuring inducible AAV production cassettes...98**
Erica Green, University of Delaware, USA
41. **Mechanistic modeling for efficient manufacturing of rAAV with the Sf9/BEVS platform...99**
Francesco Destro, Massachusetts Institute of Technology, USA
42. **DNA impurity reduction by a stably integrated staphylococcal nuclease is compatible with high-titer suspension serum-free rAAV manufacturing...100**
Geoffrey Howe, University College London, United Kingdom
43. **Optimization of scalable rAAV production for gene therapy – Leveraging at-line amino acid measurements for bioprocess modeling-driven approaches...101**
Graziella Piras, 908 Devices, Inc., USA
44. **Evaluation of small molecule antagonists of cellular innate immunity for efficient manufacturing of T-cell therapeutics...102**
Andrea Vervoort, Virica Biotech, Canada
45. **Introducing a high-performance T-cell culture medium that is free of animal derived components...103**
Joanna Kern, Thermo Fisher Scientific, USA

46. **Establishing modularity in AAV manufacturing – Deployment of engineered cell lines and advanced analytics in traditional manufacturing platforms...104**
Brandon Razooky, Resilience, USA
47. **High-yield AAV production and improved manufacturability across multiple serotypes via a novel cell engineering platform...105**
Kathy Ngo, CHO Plus, Inc., USA
48. **An efficient plasmid ratio optimization for rAAV production can be achieved using a mixture design...106**
Konstantina Tzimou, Technical University of Denmark, Denmark
49. **GlutaMAX decay offers a more sensitive indication of cell health than LDH enzymatic activity or Trypan blue exclusion...107**
Lauren Peters, Solid Biosciences, USA
50. **Metabolic phenotype of high productivity within transient transfection AAV production...108**
Margaret Moran, Solid Biosciences, USA
51. **A process development approach to a platformable and robust scale up for enrichment of full AAV capsids using membrane chromatography...109**
Mark Schofield, Cytiva, USA
52. **Process optimization and intensification of AAV2 vector production: Scale down and rapid scale up upstream processes...110**
Nazgul Wagner, Sartorius, Germany
53. **Informing next-generation cell and gene therapy technologies through an evaluation of currently approved and late clinical stage medicines...111**
Niah Goudar, Berkeley University, USA
54. **Adventitious agent control in gene therapy processing...112**
Nicholas Marchand, Cytiva, USA
55. **Assessing the impact of evolutionary pressures on the performance of AAV vector production in HEK293 cells...113**
Nikolaus Virgolini, University of Natural Resources and Life Sciences, Vienna, Austria
56. **Asymmetrical-flow field-flow fractionation and Taylor dispersion analysis for characterization of Adeno-Associated Viruses for gene therapy...114**
Nikolaus Virgolini, University of Natural Resources and Life Sciences, Vienna, Austria
57. **Assisting quality by design through design of experiments to overcome industry bottlenecks for Adeno-Associated Virus (AAV) downstream processing...115**
Paul Cashen, Sartorius, United Kingdom
58. **Continuous rAAV vector production using the baculovirus expression vector system...116**
John Joseph, Massachusetts Institute of Technology, USA
59. **Therapeutic viral vectors: Manufacturing, challenges, and platform-based innovation...117**
Rachel Legmann, Repligen, USA
60. **Plasmid engineering to improve AAV productivity and packaging efficiency...118**
Devarshi Kapadia, Lonza, USA

61. **TruStable™: A fully integrated inducible stable producer cell line for AAV manufacturing...119**
Sandhya Pande, Shape Therapeutics, USA
62. **Designing performance membranes for challenging & demanding separation applications through advanced characterization techniques...120**
Adolfo Nicoloso, Meissner, USA
63. **Animal-origin free peptones enhance adenovirus production...121**
Wen-Yang Tsai, Thermo Fisher Scientific, USA
64. **Towards a fully defined viral vector production process...122**
Nelson Ndahiro, John Hopkins University, USA